,7,8,9 Furthermore, treatment with anti-MET therapies in those patients with high-level MET amplification NSCLC induced clinical response,10 indicating that high-level MET amplification is a primary oncogenic driver for these NSCLCs.1 This evidence concerns the gene MET and non-small cell lung carcinoma.